Vigil Neuroscience’s (VIGL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report published on Thursday morning, Benzinga reports. They currently have a $17.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. JMP Securities reissued a market outperform rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, April 18th. Wedbush reissued an outperform rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, July 11th.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock opened at $4.64 on Thursday. The business’s 50-day simple moving average is $3.94 and its two-hundred day simple moving average is $3.39. The company has a market cap of $174.37 million, a PE ratio of -2.19 and a beta of 2.00. Vigil Neuroscience has a fifty-two week low of $2.47 and a fifty-two week high of $9.24.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.10. As a group, analysts predict that Vigil Neuroscience will post -2.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio purchased a new position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,200 shares of the company’s stock, valued at approximately $27,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.